Want to see GRCE full AI Analyst Report?
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-45.65% Downside)
Action:Reiterated
Date:06/19/26
Overall score reflects a pre-revenue, loss-making profile with ongoing cash burn (partly offset by low leverage and improving burn), weak technical trend signals, and meaningful regulatory risk from the FDA Complete Response Letter despite positive Phase 3 results and a path to resubmission.
Positive Factors
Phase 3 efficacy
A successful pivotal Phase 3 reduces clinical development risk and supports the product’s therapeutic rationale versus oral nimodipine. Durable clinical evidence increases the likelihood of physician adoption, reimbursement discussions, and lasting market penetration in a rare, high‑need indication once approved.
Negative Factors
Pre-revenue company
No commercial revenue over multiple years means the company remains entirely dependent on external funding and milestone-based financing. This structural absence of product cash flow prevents internal funding of growth, limits operating leverage, and maintains execution risk until launch.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 efficacy
A successful pivotal Phase 3 reduces clinical development risk and supports the product’s therapeutic rationale versus oral nimodipine. Durable clinical evidence increases the likelihood of physician adoption, reimbursement discussions, and lasting market penetration in a rare, high‑need indication once approved.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.57M
Dividend YieldN/A
Average Volume (3M)58.56K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth43.67%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding16,274,027
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.84K
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$6.00Price Target Upside30.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$5.00M
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is G...
How the Company Makes Money
null...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.07M | -23.74M | -15.37M | -24.51M | -19.17M |
| Net Income | -7.79M | -13.63M | -17.44M | -57.39M | -12.27M |
Balance Sheet | |||||
| Total Assets | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Cash, Cash Equivalents and Short-Term Investments | 16.98M | 22.13M | 23.00M | 27.89M | 43.66M |
| Total Debt | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K |
| Total Liabilities | 2.76M | 5.38M | 11.56M | 11.17M | 20.35M |
| Stockholders Equity | 63.90M | 66.61M | 61.74M | 67.95M | 108.27M |
Cash Flow | |||||
| Free Cash Flow | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Operating Cash Flow | -8.87M | -14.90M | -12.33M | -15.91M | -17.23M |
| Investing Cash Flow | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M |
| Financing Cash Flow | 3.71M | 14.03M | 7.36M | 304.00K | 0.00 |
Grace Therapeutics Technical Analysis
Positive
4.60
Price Trends
2.34
Positive
3.24
Negative
3.26
Negative
Market Momentum
-0.05
Negative
50.14
Neutral
53.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Positive. The current price of 4.6 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.34, and above the 200-day MA of 3.26, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 53.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 51 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $95.80M | -2.63 | -241.96% | ― | ― | 55.59% | |
53 Neutral | $58.14M | -4.12 | 76.02% | ― | ― | -13.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $38.57M | -3.73 | -12.66% | ― | ― | 43.67% | |
45 Neutral | $34.59M | -0.64 | -139.47% | ― | 43.88% | 14.79% | |
44 Neutral | $10.33M | -0.64 | -333.32% | ― | ― | 39.14% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
2.37
-0.63
-21.00%
PYPD
PolyPid
5.02
1.57
45.51%
ALGS
Aligos Therapeutics
5.59
-1.91
-25.47%
INKT
MiNK Therapeutics
11.67
4.66
66.48%
CVKD
Cadrenal Therapeutics, Inc.
3.60
-9.35
-72.20%
Grace Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Neutral
Jun 18, 2026
On June 18, 2026, Grace Therapeutics updated its corporate presentation to highlight progress on GTx-104, an intravenous nimodipine designed to address limitations of long-established oral standard-of-care therapy in aneurysmal subarachnoid hemorr...
Executive/Board Changes
Grace Therapeutics VP of Clinical Operations Departs Role
Neutral
Jun 5, 2026
Grace Therapeutics, Inc. reported that Vice President of Clinical Operations Carrie D’Andrea will leave her executive role and cease to be an employee effective June 5, 2026, following board approval on June 1, 2026. She is expected to recei...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Positive
Apr 27, 2026
On April 27, 2026, Grace Therapeutics updated its corporate presentation, detailing regulatory feedback and development status for its lead programs, particularly GTx-104, a novel intravenous nimodipine designed to address limitations of the long-...
Product-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Receives FDA Complete Response for GTx-104
Negative
Apr 23, 2026
On April 23, 2026, Grace Therapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for GTx-104, an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage. The FDA c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.